Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
E4/drospirenone for dysmenorrhea with ovarian endometriotic cysts
jRCT1041250190Not yet recruiting
- Sponsor
- Fuji Pharma Co., Ltd.
- Start
- Feb 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of estetrol + drospirenone in endometriosis and dysmenorrhea, sponsored by Fuji Pharma Co., Ltd. Primary endpoints: Ovarian endometriotic cyst volume reduction at cycle 3 and Ovarian endometriotic cyst volume reduction at cycle 6. Planned start Feb 2026; status: not yet recruiting.
02
Drugs
estetrol + drospirenone
03
Conditions
endometriosisdysmenorrhea
Beyond the preview
Go deeper on jRCT1041250190.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1041250190.